|
Synonyms: LP-168 | LP168
rocbrutinib is an approved drug
Compound class:
Synthetic organic
Comment: The structure for rocbrutinib was obtained from proposed INN list 129 (August 2023) where it is described as Bruton's tyrosine kinase inhibitor and antineoplastic agent. It is one of the compounds claimed in patent WO2019161152A1 (Newave Pharmaceutical) [1]. LP-168 is the one lead in Newave's development pipeline that fits the profile of a potential BTK inhibitor. Code name-to-INN was formally disclosed in 2024 [3]. Rocbrutinib binds covalently to wild-type BTK and non-covalently to mutated BTK proteins, including BTKC481 and gatekeeper mutations.
|
|
|||||||||||||||||||||||||||||||||||
For advanced searching click here to open chemical structure editor
Similar Ligands ![]() |
|||||
|
|||||